When Professors Take to the Private Market

To a life scientist who has emerged from a struggle to master a recalcitrant compound, an elusive ion flux, or an important gene sequence, launching a company might seem not just simple, but also natural. Think up a catchy name, take the CEO title, and shepherd a discovery from the laboratory to the market where profits lie. After all, don't thousands of folks—even those who think mass spectrometry may be a technical point in football—run companies and make millions from other people

Written byPeg Brickley
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

Actually, the business side of science is much more complicated than it might appear, according to biotechnology experts. Tension between a faculty member who comes up with an idea and the institution that owns it complicates the future of companies born in universities. "It's not easy anywhere," Jonathan Kaufman says. "Starting a company is a lot of work." A former academic researcher, Kaufman is now science director of Pittsburgh-based LaunchCyte, a firm that creates new biotechnology ventures. "There are faculty that consider themselves to be at odds with their institutions," he observes. "They might think, 'The university is going to get this big cut, so I'll go outside and do it on my own.' That is a pitfall."

Unlike university technology-transfer officials, most scientists lack established relationships with patent lawyers and marketing specialists. It is also rare for scientists to know as much as the officials do about negotiating the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies